VJOncology is committed to improving our service to you

GU Cancers 2020 | Erdafitinib: one more tool for bladder cancer

VJOncology is committed to improving our service to you

Arlene Siefker-Radtke

Arlene Siefker-Radtke, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses how erdafitinib improves clinical outcomes in patients suffering from FGFR3-altered urothelial cancer. This interview was recorded at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter